Patient registry of outcomes in spasticity care

Alberto Esquenazi, Nathaniel Mayer, Stella Lee, Allison Brashear, Elie Elovic, Gerard E. Francisco, Stuart Yablon

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVE: This study aimed to provide clinical injection data and real-world patient-reported and clinical outcomes for the chemodenervation and neurolytic treatment of muscle overactivity including spasticity in patients with traumatic brain injury and stroke. DESIGN: This study used a prospective multicenter observational design. The participants were 487 patients with stroke or traumatic brain injury. The interventions used were onabotulinumtoxin A or phenol. Nine subjects received both onabotulinumtoxin A and phenol. The main outcome measures were satisfaction and goal attainment, pain, and Ashworth Scale scores. RESULTS: The most commonly treated pattern of dysfunction in the upper limb was the flexed wrist, with the flexor carpi radialis as the most frequently treated muscle. The mean total dose for the upper limb muscle was 57.7 ± 34.1 U, and phenol volume was 3.9 ± 0.7 ml. The most commonly treated pattern of dysfunction in the lower limb was the equinovarus/equinus foot, with the medial/lateral gastrocnemius as the most frequently treated muscles. The mean total dose for the lower limb muscle was 93.8 ± 63.5 U, and phenol volume was 4.1 ± 1.3 ml. There was a significant improvement in Ashworth Scale and pain scores. Generally, the patients reported that they were satisfied with their treatment and made progress toward their goals. No significant treatment-related adverse effects were reported. CONCLUSIONS: Based on 487 patients with stroke and traumatic brain injury who were selected by their physician and clinical presentation for treatment using chemodenervation and neurolysis, this report of injection data reflecting actual clinical practice may serve as a further clinical guide in the management of patients with muscle overactivity, including spasticity.

Original languageEnglish (US)
Pages (from-to)729-746
Number of pages18
JournalAmerican Journal of Physical Medicine and Rehabilitation
Volume91
Issue number9
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Registries
Phenol
Muscles
Nerve Block
Stroke
Upper Extremity
Lower Extremity
Clubfoot
Pain
Injections
Therapeutics
Wrist
Foot
Outcome Assessment (Health Care)
Physicians
Traumatic Brain Injury
onabotulinumtoxinA

Keywords

  • Botulinum Toxin A
  • Muscle Overactivity
  • Phenol
  • Spasticity
  • Stroke
  • Traumatic Brain Injury

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation

Cite this

Patient registry of outcomes in spasticity care. / Esquenazi, Alberto; Mayer, Nathaniel; Lee, Stella; Brashear, Allison; Elovic, Elie; Francisco, Gerard E.; Yablon, Stuart.

In: American Journal of Physical Medicine and Rehabilitation, Vol. 91, No. 9, 01.09.2012, p. 729-746.

Research output: Contribution to journalArticle

Esquenazi, A, Mayer, N, Lee, S, Brashear, A, Elovic, E, Francisco, GE & Yablon, S 2012, 'Patient registry of outcomes in spasticity care', American Journal of Physical Medicine and Rehabilitation, vol. 91, no. 9, pp. 729-746. https://doi.org/10.1097/PHM.0b013e31824fa9ca
Esquenazi, Alberto ; Mayer, Nathaniel ; Lee, Stella ; Brashear, Allison ; Elovic, Elie ; Francisco, Gerard E. ; Yablon, Stuart. / Patient registry of outcomes in spasticity care. In: American Journal of Physical Medicine and Rehabilitation. 2012 ; Vol. 91, No. 9. pp. 729-746.
@article{601d422891ee437a91d196adf3a66120,
title = "Patient registry of outcomes in spasticity care",
abstract = "OBJECTIVE: This study aimed to provide clinical injection data and real-world patient-reported and clinical outcomes for the chemodenervation and neurolytic treatment of muscle overactivity including spasticity in patients with traumatic brain injury and stroke. DESIGN: This study used a prospective multicenter observational design. The participants were 487 patients with stroke or traumatic brain injury. The interventions used were onabotulinumtoxin A or phenol. Nine subjects received both onabotulinumtoxin A and phenol. The main outcome measures were satisfaction and goal attainment, pain, and Ashworth Scale scores. RESULTS: The most commonly treated pattern of dysfunction in the upper limb was the flexed wrist, with the flexor carpi radialis as the most frequently treated muscle. The mean total dose for the upper limb muscle was 57.7 ± 34.1 U, and phenol volume was 3.9 ± 0.7 ml. The most commonly treated pattern of dysfunction in the lower limb was the equinovarus/equinus foot, with the medial/lateral gastrocnemius as the most frequently treated muscles. The mean total dose for the lower limb muscle was 93.8 ± 63.5 U, and phenol volume was 4.1 ± 1.3 ml. There was a significant improvement in Ashworth Scale and pain scores. Generally, the patients reported that they were satisfied with their treatment and made progress toward their goals. No significant treatment-related adverse effects were reported. CONCLUSIONS: Based on 487 patients with stroke and traumatic brain injury who were selected by their physician and clinical presentation for treatment using chemodenervation and neurolysis, this report of injection data reflecting actual clinical practice may serve as a further clinical guide in the management of patients with muscle overactivity, including spasticity.",
keywords = "Botulinum Toxin A, Muscle Overactivity, Phenol, Spasticity, Stroke, Traumatic Brain Injury",
author = "Alberto Esquenazi and Nathaniel Mayer and Stella Lee and Allison Brashear and Elie Elovic and Francisco, {Gerard E.} and Stuart Yablon",
year = "2012",
month = "9",
day = "1",
doi = "10.1097/PHM.0b013e31824fa9ca",
language = "English (US)",
volume = "91",
pages = "729--746",
journal = "American Journal of Physical Medicine and Rehabilitation",
issn = "0894-9115",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Patient registry of outcomes in spasticity care

AU - Esquenazi, Alberto

AU - Mayer, Nathaniel

AU - Lee, Stella

AU - Brashear, Allison

AU - Elovic, Elie

AU - Francisco, Gerard E.

AU - Yablon, Stuart

PY - 2012/9/1

Y1 - 2012/9/1

N2 - OBJECTIVE: This study aimed to provide clinical injection data and real-world patient-reported and clinical outcomes for the chemodenervation and neurolytic treatment of muscle overactivity including spasticity in patients with traumatic brain injury and stroke. DESIGN: This study used a prospective multicenter observational design. The participants were 487 patients with stroke or traumatic brain injury. The interventions used were onabotulinumtoxin A or phenol. Nine subjects received both onabotulinumtoxin A and phenol. The main outcome measures were satisfaction and goal attainment, pain, and Ashworth Scale scores. RESULTS: The most commonly treated pattern of dysfunction in the upper limb was the flexed wrist, with the flexor carpi radialis as the most frequently treated muscle. The mean total dose for the upper limb muscle was 57.7 ± 34.1 U, and phenol volume was 3.9 ± 0.7 ml. The most commonly treated pattern of dysfunction in the lower limb was the equinovarus/equinus foot, with the medial/lateral gastrocnemius as the most frequently treated muscles. The mean total dose for the lower limb muscle was 93.8 ± 63.5 U, and phenol volume was 4.1 ± 1.3 ml. There was a significant improvement in Ashworth Scale and pain scores. Generally, the patients reported that they were satisfied with their treatment and made progress toward their goals. No significant treatment-related adverse effects were reported. CONCLUSIONS: Based on 487 patients with stroke and traumatic brain injury who were selected by their physician and clinical presentation for treatment using chemodenervation and neurolysis, this report of injection data reflecting actual clinical practice may serve as a further clinical guide in the management of patients with muscle overactivity, including spasticity.

AB - OBJECTIVE: This study aimed to provide clinical injection data and real-world patient-reported and clinical outcomes for the chemodenervation and neurolytic treatment of muscle overactivity including spasticity in patients with traumatic brain injury and stroke. DESIGN: This study used a prospective multicenter observational design. The participants were 487 patients with stroke or traumatic brain injury. The interventions used were onabotulinumtoxin A or phenol. Nine subjects received both onabotulinumtoxin A and phenol. The main outcome measures were satisfaction and goal attainment, pain, and Ashworth Scale scores. RESULTS: The most commonly treated pattern of dysfunction in the upper limb was the flexed wrist, with the flexor carpi radialis as the most frequently treated muscle. The mean total dose for the upper limb muscle was 57.7 ± 34.1 U, and phenol volume was 3.9 ± 0.7 ml. The most commonly treated pattern of dysfunction in the lower limb was the equinovarus/equinus foot, with the medial/lateral gastrocnemius as the most frequently treated muscles. The mean total dose for the lower limb muscle was 93.8 ± 63.5 U, and phenol volume was 4.1 ± 1.3 ml. There was a significant improvement in Ashworth Scale and pain scores. Generally, the patients reported that they were satisfied with their treatment and made progress toward their goals. No significant treatment-related adverse effects were reported. CONCLUSIONS: Based on 487 patients with stroke and traumatic brain injury who were selected by their physician and clinical presentation for treatment using chemodenervation and neurolysis, this report of injection data reflecting actual clinical practice may serve as a further clinical guide in the management of patients with muscle overactivity, including spasticity.

KW - Botulinum Toxin A

KW - Muscle Overactivity

KW - Phenol

KW - Spasticity

KW - Stroke

KW - Traumatic Brain Injury

UR - http://www.scopus.com/inward/record.url?scp=84865737689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865737689&partnerID=8YFLogxK

U2 - 10.1097/PHM.0b013e31824fa9ca

DO - 10.1097/PHM.0b013e31824fa9ca

M3 - Article

C2 - 22469872

AN - SCOPUS:84865737689

VL - 91

SP - 729

EP - 746

JO - American Journal of Physical Medicine and Rehabilitation

JF - American Journal of Physical Medicine and Rehabilitation

SN - 0894-9115

IS - 9

ER -